Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CSPI says Bayer nixes selenium claims

This article was originally published in The Tan Sheet

Executive Summary

Bayer discontinues claims in labeling and marketing that linked selenium in its One A Day Men's multivitamins to reduced risk of prostate cancer, according to the Center for Science in the Public Interest. However, CSPI still may pursue the lawsuit it threatened the company with in June because "Bayer adamantly insists that its claims are perfectly legal and refuses to make any commitment not to start making them again," said Stephen Gardner, CSPI's director of litigation, in an Aug. 11 e-mail. A spokeswoman declined to comment on Bayer's future plans for selenium/prostate cancer claims, though the firm previously said it was halting use of the claims in light of new science and FDA's acceptance of extremely limited health claims for selenium (1"The Tan Sheet" July 6, 2009)
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS103225

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel